home / stock / nnvc / nnvc quote
Last: | $1.13 |
---|---|
Change Percent: | 6.67% |
Open: | $1.12 |
Close: | $1.13 |
High: | $1.1699 |
Low: | $1.1 |
Volume: | 26,373 |
Last Trade Date Time: | 05/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.13 | $1.12 | $1.13 | $1.1699 | $1.1 | 26,373 | 05-03-2024 |
$1.2 | $1.155 | $1.2 | $1.2 | $1.12 | 11,733 | 05-02-2024 |
$1.13 | $1.23 | $1.13 | $1.23 | $1.13 | 7,868 | 05-01-2024 |
$1.2 | $1.1572 | $1.2 | $1.27 | $1.14 | 62,809 | 04-30-2024 |
$1.13 | $1.1 | $1.13 | $1.13 | $1.1 | 25,551 | 04-29-2024 |
$1.1 | $1.1 | $1.1 | $1.1299 | $1.1 | 5,699 | 04-26-2024 |
$1.11 | $1.11 | $1.11 | $1.1523 | $1.0297 | 26,304 | 04-25-2024 |
$1.15 | $1.14 | $1.15 | $1.15 | $1.13 | 13,981 | 04-24-2024 |
$1.14 | $1.2 | $1.14 | $1.2 | $1.11 | 11,602 | 04-23-2024 |
$1.12 | $1.1 | $1.12 | $1.1702 | $1.1 | 14,831 | 04-22-2024 |
$1.1 | $1.19 | $1.1 | $1.19 | $1.09 | 22,510 | 04-19-2024 |
$1.175 | $1.15 | $1.175 | $1.2075 | $1.15 | 13,093 | 04-18-2024 |
$1.16 | $1.18 | $1.16 | $1.23 | $1.15 | 7,733 | 04-17-2024 |
$1.18 | $1.17 | $1.18 | $1.2232 | $1.17 | 8,623 | 04-16-2024 |
$1.15 | $1.2501 | $1.15 | $1.29 | $1.13 | 75,187 | 04-15-2024 |
$1.25 | $1.295 | $1.25 | $1.3362 | $1.25 | 13,594 | 04-12-2024 |
$1.27 | $1.36 | $1.27 | $1.36 | $1.25 | 24,617 | 04-11-2024 |
$1.31 | $1.35 | $1.31 | $1.41 | $1.28 | 32,554 | 04-10-2024 |
$1.36 | $1.41 | $1.36 | $1.45 | $1.34 | 16,711 | 04-09-2024 |
$1.39 | $1.34 | $1.39 | $1.42 | $1.3204 | 35,541 | 04-08-2024 |
News, Short Squeeze, Breakout and More Instantly...
SHELTON, CT / ACCESSWIRE / April 30, 2024 / NanoViricides, Inc. (NYSE Amer: NNVC ) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that the Phase I Clinical Trial of NV-387 is completed successfully and data lock is expected soon. The Phase 1 clinical trial, ...
SHELTON, CT / ACCESSWIRE / February 15, 2024 / NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a global leader in broad-spectrum antiviral nanomedicines, reports that it has filed its Quarterly Report on Form 10-Q for the fiscal second quarter ending December 31, 2023 with the Securi...